No experience with it, but I know they always use a platinum-based chemo with another agent. There have been a couple of case reports from Japan of combining it with irinotecan:
/www.ncbi.nlm.nih.gov/pubmed/25391785/www.ncbi.nlm.nih.gov/pubmed/24594772Perhaps the most promising treatment to date has been tried by the nuclear medicine department at the University of Heidelberg. I suggest you email or call (they all speak English)
[email protected] Phone: 06221/56 7731 With the euro now at close to parity with the dollar, this medical tourism is an especially attractive option:
213Bi-DOTATOC shows efficacy in targeting neuroendocrine tumorsDOTATOC (and also DOTATEC and DOTATATE) bind to somatostatin receptors on the small cell cancer surface where it is highly expressed. This means that treatment with a somatastatin analogue (octreotide, lanreotide, or pasireotide) may be somewhat effective even without the radioactive emitter attached to it. These drugs are available now in the US, are not toxic, and your doctor can prescribe them without a clinical trial.
Another recent discovery that gives a lot of hope is that PD-L1 is highly expressed in SCPC. This
opens the door to therapies that target the PD-1/PD-L1 pathway, like Keytruda.
PD-L1 expression in small cell neuroendocrine carcinomasI think this clinical trial looks promising because it did well against small cell lung cancer in previous studies:
/clinicaltrials.gov/ct2/show/NCT02709889This one, starting in February at Duke, combines copper with disulfiram (you won't be able to drink alcohol :-() Interestingly they are using a Cu64 PET to detect it, which itself might have some activity against the cancer too (Cu 64 emits beta particles that can kill cancer cells).
/clinicaltrials.gov/ct2/show/NCT02963051Here's the full list of clinical trials, which you can review with your MO:
clinical trials for neuroendocrine PC